MARKET

TVTX

TVTX

Travere Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.27
-0.63
-3.33%
After Hours: 18.27 0 0.00% 16:20 05/14 EDT
OPEN
18.79
PREV CLOSE
18.90
HIGH
18.91
LOW
16.66
VOLUME
2.52M
TURNOVER
--
52 WEEK HIGH
33.09
52 WEEK LOW
14.50
MARKET CAP
1.10B
P/E (TTM)
-4.1895
1D
5D
1M
3M
1Y
5Y
Travere tumbles as Teva bags FDA approval for generic of Thiola
Travere Therapeutics ([[TVTX]] -9.3%) has dropped sharply in morning hours after the FDA website indicated the approval for Abbreviated New Drug Application ((ANDA)) submitted by Teva Pharmaceuticals ([[TEVA]] +2.0%) for Tiopronin Tablets,
Seekingalpha · 4h ago
Stocks That Hit 52-Week Lows On Monday
  Monday morning saw 78 companies set new 52-week lows.
Benzinga · 4d ago
70 Biggest Movers From Friday
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday.
Benzinga · 4d ago
--BMO Capital Adjusts Price Target on Travere Therapeutics to $38 From $43, Keeps Outperform Rating
MT Newswires · 05/07 14:04
--Wedbush Adjusts Price Target on Travere Therapeutics to $37 From $39 on 2021 Expense Estimates, Keeps Outperform Rating
MT Newswires · 05/07 07:42
10-Q: TRAVERE THERAPEUTICS, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and...
Edgar Online - (EDG = 10Q, 10K) · 05/06 20:53
Travere Therapeutics EPS misses by $0.25, misses on revenue
Travere Therapeutics (TVTX): Q1 Non-GAAP EPS of -$0.55 misses by $0.25; GAAP EPS of -$0.96 misses by $0.57.Revenue of $47.4M (-0.8% Y/Y) misses by $2.69M.Press Release
Seekingalpha · 05/06 20:36
Retrophin Q1 EPS $(0.55) Misses $(0.39) Estimate, Sales $47.40M Miss $50.09M Estimate
Retrophin (NASDAQ:TVTX) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.39) by 41.03 percent. This is a 175 percent decrease over losses of $(0.20) per share from the
Benzinga · 05/06 20:24
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TVTX. Analyze the recent business situations of Travere Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TVTX stock price target is 36.80 with a high estimate of 51.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 205
Institutional Holdings: 56.63M
% Owned: 93.66%
Shares Outstanding: 60.46M
TypeInstitutionsShares
Increased
47
4.79M
New
30
1.50M
Decreased
40
3.17M
Sold Out
22
2.82M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.87%
Pharmaceuticals & Medical Research
+1.14%
Key Executives
Chairman/Director
Gary Lyons
President/Chief Executive Officer/Director
Eric Dube
Chief Financial Officer/Senior Vice President
Laura Clague
Senior Vice President/General Counsel/Secretary
Elizabeth Reed
Senior Vice President
William Rote
Other
Peter Heerma
Vice President
Casey Logan
Other
Noah Rosenberg
Director
Stephen Aselage
Independent Director
Roy Baynes
Independent Director
Suzanne Bruhn
Independent Director
Timothy Coughlin
Independent Director
Jeffrey Meckler
Independent Director
John Orwin
Independent Director
Sandra Poole
Independent Director
Ron Squarer
No Data
About TVTX
Travere Therapeutics Inc., formerly Retrophin Inc., is a biopharmaceutical company. The Company specializing in identifying, developing and delivering therapies to people living with rare disease. It's pipeline includes sparsentan (RE-021), a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). Sparsentan is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A and a potent angiotensin receptor blocker (ARB). It's pipeline also includes also include OT-58, an investigational human enzyme replacement therapy. OT-58 is being developed for the treatment of classical homocystinuria (HCU). The Company's commercial products include Chenodal, Cholbam, Thiola and Thiola EC.

Webull offers kinds of Travere Therapeutics Inc stock information, including NASDAQ:TVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TVTX stock methods without spending real money on the virtual paper trading platform.